Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | CRHBP | P24387 | 1/20 | 0.64 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.64 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1306790 | 0.88 | MAPT (0.65) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL5315342 | 0.88 | MAPT (0.81) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL2252228 | 0.87 | MAPT (0.82) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL2246295 | 0.87 | MAPT (0.64) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL2248076 | 0.85 | HCAR3 (0.74) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL9192588 | 0.85 | HCAR3 (0.77) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL9725412 | 0.85 | ALDH1A1 (0.63) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL1307692 | 0.84 | MAPT (0.60) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL20797593 | 0.84 | MAPT (0.73) | MAPTALDH1A1RAB9ANPC1PKM | |
| SCHEMBL19436444 | 0.84 | PRSS1 (0.64) | MAPTALDH1A1RAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| CN-101355938-A | Pharmaceutical use of substituted amides | TRANSTECH PHARMA INC (US) | 2009-01-28 | — | — | CN | disclosed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | MAPT 3931/4885ALDH1A1 187/4885RAB9A 2870/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | MAPT 3897/4885ALDH1A1 206/4885RAB9A 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.